Comparing two treatments for advanced colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness and safety of trifluridine/tipiracil combined with regorafenib versus the same combination with bevacizumab in patients with refractory metastatic colorectal cancer. It is a multicenter, randomized, controlled, open-label trial that will assess progression-free survival, overall survival, objective response rate, disease control rate, safety, and quality of life. Patients will be monitored throughout the treatment and follow-up periods to gather comprehensive data on the outcomes of both treatment regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Sign Informed Consent Form (ICF) must be obtained during the screening visit, prior to the performance of any study procedure；
2. Male or female patient aged ≥18 years old;
3. Has histologically confirmed unresectable adenocarcinoma of the colon or rectum (all other histological types are excluded);
4. RAS status must have been previously determined (mutant or wild-type) based on local assessment of tumor biopsy;
5. Prior treatment regimens for the treatment of advanced colorectal cancer must have included a fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody and/or an anti-EGFR monoclonal antibody for RAS wildtype patients;
6. Has measurable or non-measurable disease as defined by RECIST version 1.1;
7. Is able to swallow oral tablets;
8. Estimated life expectancy ≥12 weeks;
9. ECOG PS 0-1；
10. Has adequate organ function as defined by the following laboratory values obtained within 7 days prior to randomization:

Absolute neutrophil count ≥1.5×109/L; Platelet count ≥75×109/L; Hemoglobin≥90g/L (7 days without transfusion); Creatinine clearance ≥60 mL/min, assessed using the Cockcroft \& Gault formula; Total serum bilirubin \<1.5×upper limit of normal (ULN) (unless Gilbert disease confirmed); Aspartate aminotransferase (AST; SGOT) and alanine aminotransferase (ALT; SGPT) ≤ 2.5×ULN (unless if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) ≤ 5×ULN); Urine protein \<1+ on urinalysis or 24-hour urine protein \<1g; International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5×ULN (For patients receiving anti-coagulant therapy the adequate therapeutic levels of PT should be confirmed).

Female of childbearing potential must have been tested negative in a serum pregnancy test within 7 days prior to randomization; All patients must agree to use a highly effective method of birth control as well as their partners during the study and lasting at least 6 months after the last dose.

Exclusion Criteria:

1. Prior trifluridine/tipiracil or TKI regimens for the treatment of advanced colorectal cancer;
2. Pregnancy, lactating female or possibility of becoming pregnant during the study;
3. Patients currently receiving or having received anticancer therapies within 4 weeks prior to randomization;
4. Has not recovered from clinically relevant non-hematologic CTCAE grade ≥ 3 toxicity of previous anticancer therapy prior to randomization (excluding alopecia, and skin pigmentation);
5. Has symptomatic central nervous system metastases that are neurologically unstable or requiring increasing doses of steroids to control CNS disease;
6. Has severe or uncontrolled active acute or chronic infection;
7. Has active or history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension;
8. Has any clinically significant active hepatitis, including but not limited to Hepatitis B or Hepatitis C Virus infection;
9. Known carriers of HIV antibodies;
10. Confirmed uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg) or uncontrolled or symptomatic arrhythmia;
11. Deep arterial thromboembolic events including cerebrovascular accident or myocardial infarction within the last 6 months prior to randomization;
12. Major surgery within 4 weeks prior to randomization (the surgical incision should be fully healed prior to study drug administration), or has not recovered from side effects of previous surgery, or patient that may require major surgery during the study;
13. Prior radiotherapy if completed less than 2 weeks before randomization, except if provided as a short course for symptoms palliation only;
14. Other clinically significant medical conditions; Other malignancies.

Where it's running

• The Second Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Ying Yuan, Prof. — Second Affiliated Hospital, Zhejiang University, School of Medicine
• Study coordinator: Yinuo TAN, Dr.
• Email: tan0yi0nuo@zju.edu.cn
• Phone: +86-13805753262

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• Intravenous HNF4α srRNA (CD-GA-102) for unresectable or metastatic colorectal cancer

  This trial will try IV CD-GA-102 (HNF4α srRNA) alone or with other cancer medicines to see if it is safe and can help adults with unresectable or metastatic colorectal cancer who have progressed on or cannot tolerate standard treatments.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, None Selected · NCT07050394

• ctDNA-guided choice of cetuximab versus bevacizumab with trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer

  This trial tests whether a ctDNA blood test can help choose cetuximab plus trifluridine/tipiracil versus bevacizumab plus trifluridine/tipiracil for people with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after prior treatments.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07012954

• Oral trifluridine/tipiracil with bevacizumab and sintilimab, with or without targeted radiation, for advanced MSS/pMMR colorectal cancer after two or more prior treatments

  This trial will try oral trifluridine/tipiracil combined with bevacizumab and sintilimab, with or without focused radiation, in people with advanced MSS/pMMR colorectal cancer who have progressed after at least two prior therapies.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06764680

• Second-line treatment for advanced colorectal cancer using new chemotherapy options

  This study is testing a new combination of chemotherapy drugs to see if it can help people with advanced colorectal cancer who haven't had success with their first treatment.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06540326

• Combination immunotherapy and chemotherapy for advanced colorectal cancer

  This study is testing a new treatment for patients with advanced colorectal cancer that combines immunotherapy and chemotherapy to see if it can help them better than current options.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, Forlì Cesena and 1 other locations · NCT06522919

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.